This study aimed to evaluate the lymph node pathological status after neoadjuvant therapy in Her2+ breast cancer patients and to highlight the variables that can predict a pathological complete nodal response so that it can be expected without the need for surgical axillary staging. Here, ERBB2 is linked to breast carcinoma.